I sold my Vertex shares yesterday. I think that VX 950 will be approved but I think this is already figured into the price. Preliminary work presented last fall at the liver meetings showed that nitazoxinade appears effacious in hep. c. This drug is already available and further studies are underway. I don't want to be in Vertex when the results, which I expect to be positive, are announced. In summary, I think at present there is a bigger downside being in Vertex than being out of it.
I don't believe his stock can blast off, because Romark is private. However, I share your skepticism. Until the post about knowing the Drs that had used nitazoxanide to treat HCV, baclofen1 had some credibility. The last post is a true stretch of the imagination.
It appears now that maybe baclofen1's intent is to blow up a small bit of info into a large balloon to impact Vertex. I think the first few responses have him pegged.
Just my humble opinion.
I know doctors personally who have prescribed alinia. In cases of people with genotype 1 who do not have EVR or response at week 24, alinia has been prescribed after discussion with the patient of the "experimental" nature of alinia in such situations. It is either that or stopping Rx and waiting until VX 950 is approved.
it doesn't seem prudent to ignore a possible competitor of TVR. Bocepravir and others are on the radar screen, no reason not to include this one.
I am not ready to clear my VRTX position for sure, but nitazoxanide does have the advantage of being approved and available for use. Publication of papers by Romark will draw ti to the attention of HCV specialists. As a result, it could be used off label and, if a physician gets comfortable with it, could establish a regular level of usage during the time TVR is in development.
It has been approved to treat cryptosporidium and Giardia for some time, experience with safety and side effects should be pretty clear.
It is interesting that as far as I know you never posted here before and now you are posting negative comments after the quarterly report. That is usually when shorts start posting negative comments -- right after quarterly reports or after a major news announcement!
I have no position in VRTX. Regarding nitazoxanide, it is being tested in genotype 1 at present. Of course I do not know what the results will show. However, it is important to remember that this drug is already available and can be, and in fact is, being prescribed off label. I would not want to be in VRTX if Romark reports promising results. I would also point out that one of the most prominent hepatologists in the country, Emmett Keefe of Stanford Univ.. has taken a high position with Romark.
Romark, the owner of nitazoxanide, has yet to complete any study, using nitazoxanide in Geno 1 patients. (Geno 1 being the most common in Europe and the US and the most difficult to treat.) In fact, they only recently starte a Phase II in Geno 1. Also, they have yet to complete any study in the US or Europe for nitazoxanide as a treatment for HCV.
It would be great if they are successful, but they are many years behind.